## Supporting information for: Switching from adduct formation to electron transfer in a light-oxygen-voltage domain containing the reactive cysteine

Kathrin Magerl, Ivan Stambolic, and Bernhard Dick\*

Institute of Physical and Theoretical Chemistry, University of Regensburg, Universitaetsstrasse 31, 93053 Regensburg, Germany

> E-mail: bernhard.dick@chemie.uni-regensburg.de Phone: +49 (0)941 943 4486. Fax: +49 (0)941 943 4488

#### 1. Mutagenesis

The gene encoding for the cDNA of CrLOV1 wt was used as a template for site-directed mutagenesis. PCR was performed using Pfu DNA polymerase (Thermo Scientific, Waltham, MA, US) and the primers given in table S1. The sequence of the plasmids carrying the desired nucleotide substitutions was confirmed by DNA sequencing (Seqlab Sequence Laboratories, Göttingen, Germany)

T 11 C1	OI	1 1 1	•	1	r 1	• 1•	4 1	4	•
Table SL.	Uligoniic	leotide p	rimers	11Sed 1	tor si	11.e - d1'	rected	mutage	2nesis
TUDIO DI.	Ongonae	roomae p	<b>THIOLD</b>	aboa	LOT DI	100 GI.	rootoa	manage	110010

Primer name	DNA base sequence $(5' \text{ to } 3')$
CrLOV1 - F41Y - s <sup>a</sup>	$CAGCGAGGGGTATTa^{b}TGCCATGAC$
$\rm CrLOV1$ - F41Y - as $^a$	GTCATGGCAtAATACCCCTCGCTG
m CrLOV1 - $ m C57S$ - s	GTGCTTGGTCACAACaGCCGCTTCCT
m CrLOV1 - $ m C57S$ - as	AGGAAGCGGCtGTTGTGACCAAGCAC
m CrLOV1 - $ m C57A$ - $ m s$	CTTGTTCACAACgcgCGCTTCCTC
m CrLOV1 - $ m C57A$ - as	GAGGAAGCGcgcGTTGTGACCAAG
m CrLOV1 - $ m C57G$ - $ m s$	gGCCGCTTCCTCCAAGGCGAGGGCACGGACCCCAA
$\rm CrLOV1$ - $\rm C57G$ - as	CTTGGAGGAAGCGGCcGTTGTGACCAAGCACCTCATCGG
<sup>a</sup> s. sense primer: as: a	ntisense primer $^{b}$ The mutated DNA bases in the specific codons are

s: sense primer; as: antisense primer <sup>o</sup> The mutated DNA bases in the specific codons are highlighted by small letters.

### 2. UV / Vis spectra of the different CrLOV1-F41Y mutants

UV / Vis spectra of the CrLOV1-F41Y mutants were recorded in the range of 300-600 nm using a Lambda 9a spectrometer (Perkin Elmer, Waltham, MA, US). Spectra were recorded before and after transient absorption measurements in order to control the stability of the samples.

Figure S1 shows the mutants CrLOV1-F41Y, CrLOV1-F41Y/C57S, CrLOV1-F41Y/C57A and CrLOV1-F41Y/C57G in comparison with the wild type. All mutants exhibit the typical fine structured absorption bands around 445 nm and 360 nm, showing only minor wavelength shifts compared to the wild type.



Figure S1: UV / Vis spectra of the CrLOV1-F41Y mutants measured in the range of 300-600 nm.

Table S2: Absorption maxima of the  $S_0 \rightarrow S_1$  and  $S_0 \rightarrow S_2$  transitions of the CrLOV1 mutants.

	$S_0 \rightarrow S_1$	$S_0 \rightarrow S_2$
	(nm)	(nm)
F41Y	422/445/473	368  /  352
F41Y/C57A	424  /  446  /  473	367/352
F41Y/C57S	422/444/470	365/354
F41Y/C57G	425  /  447  /  474	368/354

# 3. Interpretation of the D<sub>2</sub> of CrLOV1-F41Y/C57S and CrLOV1-F41Y/C57A

A contribution of FMNH<sup>•</sup> and the corresponding radical of the electron donor Tyr were assumed to be neccessary to describe the DADS associated with the slower decaying species of CrLOV1-F41Y/C57S and F41Y/C57A. In the case of F41Y/C57S the linear combination of FMNH<sup>•</sup>, FMNox and TyrO<sup>•</sup> was not sufficient to describe D<sub>2</sub> in figure S2A adequately. Taking into account a contribution of the FMN radical anion, FMN<sup>•–</sup>, results in the red line in figure S2A and is in good agreement with the DADS.

In contrast,  $D_2$  of CrLOV1-F41Y/C57A (figure S2B) could be best described using a linear combination of FMNH<sup>-</sup> plus FMN<sup>--</sup> minus FMNox. In this case, the contribution of the FMN

radical anion is larger and the contribution of TyrO' did not improve the spectral fitting. Thus, we can not prove unequivocably that TyrO' is stabilized as the counter-radical of FMNH' in CrLOV1-F41Y/C57A.



Figure S2: A:  $D_2$  of CrLOV1-F41Y/C57S (black line) obtained by global lifetime analysis. The spectrum could be described in good agreement by using a linear combination (fit, red line) of FMNH<sup>•</sup>, FMN<sup>•-</sup>, FMNox and TyrO<sup>•</sup>. B:  $D_2$  of CrLOV1-F41Y/C57A (black line) could be best described by using a linear combination (fit, red line) of FMNH<sup>•</sup>, FMN<sup>•-</sup> and FMNox. In this case, inclusion of TyrO<sup>•</sup> did not improve the result.

### 4. DADS of CrLOV1-F41Y/C57G

The transient absorption measurement of CrLOV1-F41Y/C57G was performed on a 100  $\mu$ s streak window with laser excitation at 447 nm. Global lifetime analysis of the resulting 2D TA data matrix using two exponential functions results in the DADS shown in figure S3.

Both DADS exhibit characteristic features of the FMN triplet state indicating a biphasic triplet decay like already observed for CrLOV1-C57G.<sup>1</sup> Further details are described in the main text of this publication. However it is noteworthy, that the ground state bleach of FMNox in D<sub>2</sub> is not recovering proportionally to the decrease of positive absorption signals in comparison with D<sub>1</sub>. This is due to irreversible photo-damage of some fraction of CrLOV1-F41Y/C57G during the TA measurement.



Figure S3: DADS of CrLOV1-F41Y/C57G obtained by global lifetime analysis . A: D<sub>1</sub> decaying with a rate constant of 28.0  $\mu$ s B: D<sub>2</sub> non-decaying within 100.0  $\mu$ s.

### Dihedral angle distribution between F41Y and FMN

Dihedral angle distributions between Tyr41-CE2, FMN- (C5a-C4a) and Tyr41-CE1 of all CrLOV1-F41Y mutants obtained from analyzing the 20 ns MD trajectories. The distribution curves are broad in all cases with varying maxima from 18° (F41Y/C57S) to 22.5° (F41Y).

CrLOV1-F41Y/C57A additionally has a second minor peak. The dihedral angle distribution indicate a considerable flexibility between Tyr41 and FMN possibly leading to different geometry - dependent reaction pathways.



Figure S4: Dihedral angle distributions between Tyr41-CE2, FMN-(C5a-C4a) and Tyr41-CE1 of all CrLOV1-F41Y mutants.

### References

 Kutta, R. J.; Magerl, K.; Kensy, U.; Dick, B. Photochem. Photobiol. Sci. 2015, 14, 288-299.